Catherine C. Smith

12.2k total citations · 3 hit papers
106 papers, 3.7k citations indexed

About

Catherine C. Smith is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Catherine C. Smith has authored 106 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Hematology, 42 papers in Genetics and 27 papers in Molecular Biology. Recurrent topics in Catherine C. Smith's work include Acute Myeloid Leukemia Research (59 papers), Chronic Myeloid Leukemia Treatments (48 papers) and Chronic Lymphocytic Leukemia Research (33 papers). Catherine C. Smith is often cited by papers focused on Acute Myeloid Leukemia Research (59 papers), Chronic Myeloid Leukemia Treatments (48 papers) and Chronic Lymphocytic Leukemia Research (33 papers). Catherine C. Smith collaborates with scholars based in United States, Japan and United Kingdom. Catherine C. Smith's co-authors include Neil P. Shah, Alexander E. Perl, Rudolf Štětina, Lisa Giovannelli, Andrew Collins, Gunnar Brunborg, Isabel Gaivão, Marcin Kruszewski, Á. Oscoz and Mike O’Donovan and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Catherine C. Smith

100 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The comet assay: topical issues

2008 776 citations Andrew Collins, Á. Oscoz et al. Mutagenesis profile →
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

2012 542 citations Catherine C. Smith, Chen-Shan Chin et al. profile →
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

2022 123 citations Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Catherine C. Smith

Since Specialization

Citations

This map shows the geographic impact of Catherine C. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine C. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine C. Smith more than expected).

Fields of papers citing papers by Catherine C. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine C. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine C. Smith. The network helps show where Catherine C. Smith may publish in the future.

Co-authorship network of co-authors of Catherine C. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine C. Smith. A scholar is included among the top collaborators of Catherine C. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine C. Smith. Catherine C. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SNACS: a tool for demultiplexing single-cell DNA sequencing data 2025 ·Bioinformatics ·Vanessa E. Kennedy, Ritu Roy, Cheryl A.C. Peretz, (unknown), (unknown), Catherine C. Smith, Adam B. Olshen	1
2	Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML 2025 ·Blood ·Bogdan Popescu, Matthew F. Jones, (unknown), (unknown), (unknown), (unknown), Cheryl A.C. Peretz, (unknown), (unknown), (unknown), José M. Rivera, (unknown), (unknown), Yana Pikman, Michael L. Cheng, Aaron C. Logan, Benjamin J. Huang, Elliot Stieglitz, Catherine C. Smith	1
3	Patient Perspectives on Technological Barriers and Implementation Strategies Leveraged During a Real-World Remote Symptom Monitoring Program 2025 ·JCO Clinical Cancer Informatics ·(unknown), (unknown), (unknown), (unknown), Catherine C. Smith, Chao‐Hui Huang, Tara Kaufmann, (unknown), Jennifer Young Pierce, Stacey A. Ingram, Angela M. Stover, Ethan Basch, Doris Howell, Bryan J. Weiner, J. Nicholas Dionne‐Odom, Gabrielle B. Rocque	0
4	A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia 2024 ·Blood Advances ·Mark J. Levis, Alexander E. Perl, Gary J. Schiller, Amir T. Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Trivikram Rajkhowa, Makoto Ando, (unknown), Ruth Ann Subach, (unknown), Timothy Madden, Mary Johansen, K.Y. Cheung, Michael R. Kurman, Catherine C. Smith	9
5	Patient and provider perceptions of the benefits and limitations of implementing ePRO-driven remote symptom monitoring into real-world cancer care settings. 2024 ·JCO Oncology Practice ·Catherine C. Smith, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Courtney Williams, Chao‐Hui Huang, (unknown), Stacey A. Ingram, J. Nicholas Dionne‐Odom, Bryan J. Weiner, Doris Howell, Angela M. Stover, Ethan Basch, Jennifer Young Pierce, Gabrielle B. Rocque	0
6	Complex Genomic Rearrangements Involving ETV6::ABL1 Gene Fusion in an Individual with Myeloid Neoplasm 2023 ·Genes ·Zhongxia Qi, Catherine C. Smith, Neil P. Shah, (unknown)	1
7	Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML 2023 ·Cell Reports Medicine ·Bogdan Popescu, Carlos Stahlhut, (unknown), (unknown), Bianca J. Lee, Cheryl A.C. Peretz, (unknown), (unknown), Juan A. Cámara, (unknown), Jose Rivera, (unknown), (unknown), Veronica Steri, Sarah K. Tasian, Elliot Stieglitz, Catherine C. Smith	6
8	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia breakdown → 2022 ·Journal of Clinical Oncology ·Naval Daver, Alexander E. Perl, Joseph Maly, Mark J. Levis, Ellen K. Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramón V. Tiu, Kiran Naqvi, Monique Dail, Deanna J. Brackman, (unknown), Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman	123
9	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib 2022 ·Blood Cancer Journal ·Alexander E. Perl, Naoko Hosono, Pau Montesinos, Nikolai A. Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Récher, Catherine C. Smith, Mark J. Levis, Stephen A. Strickland, Christoph Röllig, (unknown), Wen‐Chien Chou, Je‐Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramón V. Tiu, Jessica K. Altman	27
10	Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia 2021 ·Clinical Cancer Research ·Catherine C. Smith, Aaron D. Viny, Evan Massi, Cyriac Kandoth, Nicholas D. Socci, Franck Rapaport, (unknown), Juan S. Medina-Martínez, Elli Papaemmanuil, (unknown), Henry H. Hsu, Mai H. Le, Brian L. West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, Neil P. Shah	11
11	Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor 2020 ·Clinical Pharmacokinetics ·(unknown), Catherine C. Smith, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman, Dale R. Shepard, Takeshi Kadokura, (unknown), (unknown), Zheng‐Rong Lu, Chaofeng Liu, Selina Moy, Mark J. Levis, Erkut Bahceci	50
12	Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis 2017 ·Blood ·Catherine C. Smith, Amy L. Paguirigan, Grace R. Jeschke, Kimberly C. Lin, Evan Massi, (unknown), Chen-Shan Chin, Saurabh Asthana, Adam B. Olshen, Kevin Travers, Susana Wang, Mark J. Levis, Alexander E. Perl, Jerald P. Radich, Neil P. Shah	120
13	The Novel, Irreversible FLT3 Inhibitor FF-10101 Demonstrates Broad in Vitro Activity Against FLT3 Inhibitor Resistance Mutations 2017 ·Blood ·Timothy T. Ferng, (unknown), Catherine C. Smith	1
14	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia 2016 ·JCI Insight ·Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, (unknown), Alisa B. Lee‐Sherick, (unknown), Elisabeth A. Lasater, (unknown), Michael A. Stashko, Weihe Zhang, Craig T. Jordan, Dmitri Kireev, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Neil P. Shah, Douglas K. Graham	61
15	Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis 2014 ·Cell Reports ·Anindya Chatterjee, Joydeep Ghosh, Baskar Ramdas, Raghuveer Singh Mali, Holly Martin, Michihiro Kobayashi, Sasidhar Vemula, (unknown), (unknown), Valeria Visconte, Ramón V. Tiu, Catherine C. Smith, Neil P. Shah, Kevin D. Bunting, (unknown), Yan Liu, Rebecca J. Chan, Reuben Kapur	45
16	Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients 2014 ·Journal of Geriatric Oncology ·Jesse W. Keller, Charalambos Andreadis, Lloyd E. Damon, Lawrence D. Kaplan, Thomas Martin, Jeffrey L. Wolf, Weiyun Z. Ai, Jeffrey M. Venstrom, Catherine C. Smith, Karin Gaensler, Jimmy Hwang, Rebecca L. Olin	10
17	The comet assay: topical issues breakdown → 2008 ·Mutagenesis ·Andrew Collins, Á. Oscoz, Gunnar Brunborg, Isabel Gaivão, Lisa Giovannelli, Marcin Kruszewski, Catherine C. Smith, Rudolf Štětina	776
18	DNA damage responses after exposure to DNA‐based products 2005 ·The Journal of Gene Medicine ·Catherine C. Smith, (unknown), Krishna J. Fisher, Anthony M. Lynch, Nigel J. Gooderham	11
19	Seed transmission and pathology of Corynebacterium flaccumfaciens in beans (Phaseolus vulgaris). 1983 ·Seed Science and Technology ·(unknown), Catherine C. Smith	1
20	Population trends of epiphytic Corynebacterium nebraskense on leaves of popcorn genotypes. 1983 ·Fitopatologia Brasileira ·M. L. Schuster, Catherine C. Smith, David J. Smith	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact